Clinical Trials
5
Active:0
Completed:3
Trial Phases
2 Phases
Phase 2:3
Not Applicable:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (60.0%)Not Applicable
2 (40.0%)MCC-24-GYN-11: Comparison of Nodal Sampling in Endometrial Cancer
Not Applicable
Recruiting
- Conditions
- Endometrial Cancer
- First Posted Date
- 2024-11-06
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Rachel Miller
- Target Recruit Count
- 625
- Registration Number
- NCT06677112
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
Chemotherapy-Induced Cognitive Impairment in Ovarian Cancer Patients
Not Applicable
Completed
- Conditions
- Chemotherapy-induced Cognitive Impairment
- First Posted Date
- 2017-10-30
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- Rachel Miller
- Target Recruit Count
- 14
- Registration Number
- NCT03324945
- Locations
- 🇺🇸
University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
Phase 2
Recruiting
- Conditions
- Cancer
- Interventions
- Drug: Therapeutic Intervention
- First Posted Date
- 2017-03-24
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Rachel Miller
- Target Recruit Count
- 93
- Registration Number
- NCT03089554
- Locations
- 🇺🇸
Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States
Biobehavioral Intervention in Gynecologic Oncology Patients
Phase 2
Completed
- Conditions
- VulvaOvarian NeoplasmsNeoplasmsUterine Neoplasms
- First Posted Date
- 2015-05-27
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- Rachel Miller
- Target Recruit Count
- 6
- Registration Number
- NCT02454036
- Locations
- 🇺🇸
Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States
Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma
Phase 2
Completed
- Conditions
- Fallopian Tube CarcinomaPrimary Peritoneal CarcinomaOvarian Carcinoma
- Interventions
- Drug: neoadjuvant chemotherapy
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2020-12-14
- Lead Sponsor
- Rachel Miller
- Target Recruit Count
- 28
- Registration Number
- NCT01519869
- Locations
- 🇺🇸
University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States
News
No news found